Selective use of adrenal venous sampling in the lateralization of aldosterone-producing adenomas. 2006

Yah Yuen Tan, and Jennifer B Ogilvie, and Frederick Triponez, and Nadine R Caron, and Electron K Kebebew, and Orlo H Clark, and Quan-Yang Duh
Department of Surgery, University of California San Francisco, 4150 Clement Street, San Francisco, California 94121, USA.

BACKGROUND It has been suggested that routine adrenal venous sampling (AVS) is necessary to lateralize an aldosterone-producing adenoma in patients with primary hyperaldosteronism. However, the success rate of AVS is variable, with potential risks. We review our experience at University of California San Francisco (UCSF), where AVS is used only selectively, to determine outcomes with this approach. METHODS All patients undergoing adrenalectomy for aldosteronoma at UCSF from January 1995 to October 2004 were included. Outcome after adrenalectomy was determined based on plasma levels of aldosterone and potassium, rates of persistent hypertension, and reduced use of antihypertensive medications. RESULTS Altogether, 65 patients were included in the study, 52 (80%) of whom had their adrenal tumors lateralized based on computed tomography scans, magnetic resonance imaging, or both. The remaining 13 (20%) patients had doubtful localization of their lesions on imaging. We did not routinely perform AVS in patients with definitive imaging findings. Thus, only 4 (8%) patients with definitive imaging findings underwent AVS, and one was unsuccessful. Of the 13 patients with doubtful lateralization on imaging, 8 underwent AVS. With this practice, biochemical cure rates after adrenalectomy were up to 100%, and hypertension resolved or was improved in 85% of patients. CONCLUSIONS AVS may be performed selectively only when preoperative imaging cannot definitively lateralize the aldosteronoma. This practice in our center has resulted in high cure rates. During the era of improved imaging resolution and experience, mandatory routine AVS is not necessary to achieve high cure rates for aldosteronomas.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006929 Hyperaldosteronism A condition caused by the overproduction of ALDOSTERONE. It is characterized by sodium retention and potassium excretion with resultant HYPERTENSION and HYPOKALEMIA. Aldosteronism,Conn Syndrome,Conn's Syndrome,Primary Hyperaldosteronism,Conns Syndrome,Hyperaldosteronism, Primary,Syndrome, Conn,Syndrome, Conn's
D000236 Adenoma A benign epithelial tumor with a glandular organization. Adenoma, Basal Cell,Adenoma, Follicular,Adenoma, Microcystic,Adenoma, Monomorphic,Adenoma, Papillary,Adenoma, Trabecular,Adenomas,Adenomas, Basal Cell,Adenomas, Follicular,Adenomas, Microcystic,Adenomas, Monomorphic,Adenomas, Papillary,Adenomas, Trabecular,Basal Cell Adenoma,Basal Cell Adenomas,Follicular Adenoma,Follicular Adenomas,Microcystic Adenoma,Microcystic Adenomas,Monomorphic Adenoma,Monomorphic Adenomas,Papillary Adenoma,Papillary Adenomas,Trabecular Adenoma,Trabecular Adenomas
D000310 Adrenal Gland Neoplasms Tumors or cancer of the ADRENAL GLANDS. Adrenal Cancer,Adrenal Gland Cancer,Adrenal Neoplasm,Cancer of the Adrenal Gland,Neoplasms, Adrenal Gland,Adrenal Cancers,Adrenal Gland Cancers,Adrenal Gland Neoplasm,Adrenal Neoplasms,Cancer, Adrenal,Cancer, Adrenal Gland,Cancers, Adrenal,Cancers, Adrenal Gland,Neoplasm, Adrenal,Neoplasm, Adrenal Gland,Neoplasms, Adrenal
D000315 Adrenalectomy Excision of one or both adrenal glands. (From Dorland, 28th ed) Adrenalectomies
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Yah Yuen Tan, and Jennifer B Ogilvie, and Frederick Triponez, and Nadine R Caron, and Electron K Kebebew, and Orlo H Clark, and Quan-Yang Duh
November 2007, Hypertension research : official journal of the Japanese Society of Hypertension,
Yah Yuen Tan, and Jennifer B Ogilvie, and Frederick Triponez, and Nadine R Caron, and Electron K Kebebew, and Orlo H Clark, and Quan-Yang Duh
June 2016, Journal of human hypertension,
Yah Yuen Tan, and Jennifer B Ogilvie, and Frederick Triponez, and Nadine R Caron, and Electron K Kebebew, and Orlo H Clark, and Quan-Yang Duh
August 2023, Surgery,
Yah Yuen Tan, and Jennifer B Ogilvie, and Frederick Triponez, and Nadine R Caron, and Electron K Kebebew, and Orlo H Clark, and Quan-Yang Duh
March 2024, The Journal of clinical endocrinology and metabolism,
Yah Yuen Tan, and Jennifer B Ogilvie, and Frederick Triponez, and Nadine R Caron, and Electron K Kebebew, and Orlo H Clark, and Quan-Yang Duh
January 2016, Endocrine journal,
Yah Yuen Tan, and Jennifer B Ogilvie, and Frederick Triponez, and Nadine R Caron, and Electron K Kebebew, and Orlo H Clark, and Quan-Yang Duh
February 2017, Journal of hypertension,
Yah Yuen Tan, and Jennifer B Ogilvie, and Frederick Triponez, and Nadine R Caron, and Electron K Kebebew, and Orlo H Clark, and Quan-Yang Duh
February 1993, Nihon Naibunpi Gakkai zasshi,
Yah Yuen Tan, and Jennifer B Ogilvie, and Frederick Triponez, and Nadine R Caron, and Electron K Kebebew, and Orlo H Clark, and Quan-Yang Duh
July 2017, Journal of human hypertension,
Yah Yuen Tan, and Jennifer B Ogilvie, and Frederick Triponez, and Nadine R Caron, and Electron K Kebebew, and Orlo H Clark, and Quan-Yang Duh
August 2023, Endocrinology, diabetes & metabolism case reports,
Yah Yuen Tan, and Jennifer B Ogilvie, and Frederick Triponez, and Nadine R Caron, and Electron K Kebebew, and Orlo H Clark, and Quan-Yang Duh
April 2020, Clinical nuclear medicine,
Copied contents to your clipboard!